Advertisement
HLUKF.OB Forex Haberleri
FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease. This is the first FDA-approved treatment option for this indication. The supplemental approval of Rexulti was granted to Otsuka Pharmaceutical Co. Ltd., and Lundbeck Inc.
RTTNews
|
816 gün önce
